مباشر

Endpoints NewsLilly points to low-dose Zepbound and Foundayo as weight loss maintenance options IlluminaThe Bull Case For Illumina (ILMN) Could Change Following Upgraded 2026 Outlook And Major Buyback - Learn Why - simplywall.st FierceBiotechFDA Commissioner Marty Makary to resign, capping turbulent tenure: report FierceBiotechKyverna begins rolling submission for autoimmune CAR-T as FDA requests more natural history analysis Clinical OMICsLow‑Dose Digoxin Shows Benefit in Heart Failure Treatment Clinical OMICsAntibody Promotes Nerve Regeneration in Spinal Cord Injury Patients Clinical OMICsSingle Procedure Reduces Colorectal Cancer Risk Decades Later 10x Genomics News10x Genomics settles suit with rival and targets DNA sequencing startup - Life Sciences Intellectual Property Review Clinical OMICsFirst Clinical Trial for a GLP-1 Gene Therapy Greenlit in Europe BioPharma DiveFDA chief Marty Makary resigns from agency, ending tumultuous tenure Endpoints NewsEU reaches provisional deal on Critical Medicines Act Endpoints NewsFDA Commissioner Makary to resign, source says

FierceBiotech ١٢ مايو ٢٠٢٦

Kyverna begins rolling submission for autoimmune CAR-T as FDA requests more natural history analysis

Kyverna Therapeutics has officially started a rolling submission to the FDA for miv-cel as the company conducts additional natural history analysis at the agenc...

Kyverna Therapeutics has officially started a rolling submission to the FDA for miv-cel as the company conducts additional natural history analysis at the agency's request, keeping the candidate on track to be the first autoimmune CAR-T to reach the market.